GlobeNewswire

Fentress Architects: The Future of Airports as Civic Spaces

Dela

The European Cultural Centre and Global Art Affairs Foundation invited Fentress Architects and North Carolina State University College of Design to participate in the 2018 Venice Architecture Biennale May 26-November 25, 2018, at the historic Palazzo Bembo.

 

Denver, Colo. - May 21, 2018, May 21, 2018 (GLOBE NEWSWIRE) --

Architecture students from North Carolina State University College of Design will join Fentress at the Palazzo Bembo to present their designs for airports of the future. Fentress has been guiding students in preparation for the exhibition, which allows 11 students to embark on a once-in-a-lifetime opportunity to travel to Italy for the 2018 Venice Biennale of Architecture. Their designs will be featured in the "Time Space Existence" exhibit, offering the public a glimpse at the future of airport design. The students are participating in an Airport Design course with Principal in Charge of Design Curt Fentress, FAIA, RIBA, and Alumni Distinguished Professor of Architecture Wayne Place, Ph.D. that focuses on designing airports that reflect the context and culture of their location.

Fentress helped create the NC State University College of Design airport design studio in 2013. The studio focuses on airports as a building type that establishes civic spaces. Students are challenged to design airports for various locations around the world. As part of this process, student design teams research the culture, climate, and terrain of their chosen location. By the end of the course, students know how to implement flexible design strategies to create world-class airports that reflect a sense of place.

Curt Fentress, FAIA, RIBA, is an alumnus and valuable supporter of the College of Design. "It's very exciting to see how these architectural minds are transforming the future of airport design," says Curt Fentress. Graduate student Cameron Westbrook, who is currently participating in the studio, says, "It's been a good experience to work with Fentress Architects. It's been eye-opening because there's so much technology and so much planning to incorporate within the early stages of designing an airport. It can be overwhelming, but it also puts us in a position to want to know more. They [Fentress] are also very encouraging."

Invited by the European Cultural Centre and Global Art Affairs Foundation, Fentress Architects will return to the 2018 Venice Biennale of Architecture to present Now Boarding - Fentress Architects: Airports as Civic Spaces. Fentress made its debut at the Biennale in 2016 with its Now Boarding exhibition, celebrating the past, present, and future of airport design. This year the firm's exhibition will feature airports as civic spaces, showcasing the concept of humanism flowing through airports. Through the use of film, photographs, and models, the exhibition showcases the transformation of the passenger experience in contemporary airport design. The concept of airports as civic spaces is explored through Fentress designs for five airport terminals:

·  South Terminal Complex at Orlando International Airport (MCO)

·  Incheon International Airport (ICN)

·  Seattle-Tacoma International Airport (SEA)

·  Denver International Airport (DEN)

·  Tom Bradley International Terminal at Los Angeles International Airport (LAX)

About the Biennale

The Venice Biennale is one of the most prestigious international cultural events in the world. By inviting the world's leading design thinkers, visionaries, and makers, the Biennale consistently cultivates a progressive voice that inspires, advocates, and connects a global audience. The Biennale and associated exhibitions are hosted throughout the island of Venice, imbuing the city's historic past as an international center for arts and culture with modern significance, while maintaining Venice's status as a premier destination. All told, over a quarter million people visited the last Architecture Biennale, with millions more accessing the exhibition via press and other media.

About Palazzo Bembo

Now Boarding - Fentress Architects: Airports as Civic Spaces and the College of Design exhibition will be featured at the historic Palazzo Bembo, overlooking the Grand Canal and just steps from the centrally-located Rialto Bridge. The Palazzo was built by the noble Bembo family in the 15th century, and its architectural style reflects the Venetian influences of its original period and those from subsequent restorations. Among the ancient families of Venetian aristocracy, the Bembo lineage includes saints, leaders, heroes, and writers. The Bembo font, a popular serif typeface, traces its origins to the family.

About the North Carolina State College of Design

The NC State College of Design prepares students for a career in design through interdisciplinary engagement, innovative exploration of technologies, and a core foundation of design thinking and practice. The College of Design offers undergraduate, graduate, Doctor of Design [DDes], and Ph.D. in design degrees and currently has 850 enrolled students. NC State University is a leading public research university located in Raleigh, North Carolina. In response to an ever-expanding global interest in all disciplines of design, the College's curriculum incorporates relevant practices reflecting both the University's research, its number one status in the state, and its land-grant mission. Effective design requires attention and sensitivity to the social, economic, political, cultural, and behavioral understanding of the environment and people. Our graduate and undergraduate programs in Architecture, Art + Design, Design Studies, Graphic Design, Industrial Design, and Landscape Architecture are intended to de­velop a designer's perception, knowledge, skills, and problem-solving abilities to develop design solutions for public interest, to serve the needs of all users, and to impact the myriad of sustainability and life-quality problems across the globe.

design.ncsu.edu
 
 
Fentress Architects is a global design firm that passionately pursues the creation of sustainable and iconic architecture. Together with its clients, Fentress creates inspired design to improve the human environment. Founded by Curtis Fentress in 1980, the firm has designed $42 billion of architectural projects worldwide, visited by more than 550 million people each year. Fentress is a dynamic learning organization, driven to grow its ability to design, innovate and exceed client expectations. The firm has been honored with more than 500 distinctions for design excellence and innovation.

Fentress has studios in Denver, Colorado; Washington, D.C.; Los Angeles and San Francisco, California; and London, U.K. www.fentressarchitects.com

Attachments

Julian Fentress
Fentress Architects
303 698 7298
jfentress@fentressarchitects.com
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Fentress Architects via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum